Increased prevalence of autoimmune phenomena and greater risk for alloreactivity in female heart transplant recipients.
BACKGROUND
The influence of sex on alloreactivity and graft outcome after heart transplantation was evaluated.


RESULTS
A retrospective review of 520 consecutive recipients of a primary cardiac allograft between 1992 and 2000 at a single center was performed. The influence of sex on alloreactivity, acute rejection, transplant-related coronary artery disease, and survival was determined. Statistical methods included logistic regression analysis and Kaplan-Meier actuarial survival analysis. Female recipients had an increased prevalence before transplant of idiopathic cardiomyopathy, antinuclear antibodies, and HLA-B8, DR3 haplotypes. After transplant, female sex predicted shorter duration to a first rejection, higher cumulative rejection frequency, and earlier posttransplant production of anti-HLA antibodies. Female recipients had higher early mortality rates (<6 months) that were due to infection. Fatal infections correlated with 2-fold higher cyclosporine levels in female recipients. However, the incidence of transplant-related coronary artery disease developing beyond 1 year after transplant was lower in female than in male recipients.


CONCLUSIONS
Females undergoing cardiac transplantation are more likely to manifest features of an underlying autoimmune state. This may predispose to a higher posttransplant risk of allograft rejection and requirement for increased immunosuppression. Earlier diagnosis and management of alloreactivity in female recipients before development of acute rejection and the use of more focused and less globally immunosuppressive agents during established rejections may have a significant effect on the clinical outcome of female cardiac allograft recipients.
Lietz
K
K
Division of Cardiothoracic Surgery, Columbia Presbyterian Medical Center, Columbia University, New York, NY, USA.
John
R
R
Kocher
A
A
Schuster
M
M
Mancini
D M
DM
Edwards
N M
NM
Itescu
S
S
D001323:Autoantibodies / Q000097:blood; D001327:Autoimmune Diseases / Q000175:diagnosis / Q000453:epidemiology* / Q000276:immunology; D002423:Cause of Death; D015331:Cohort Studies; D015897:Comorbidity; D003327:Coronary Disease / Q000175:diagnosis / Q000453:epidemiology* / Q000276:immunology; D003710:Demography; D018572:Disease-Free Survival; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology* / Q000276:immunology; D006680:HLA Antigens / Q000276:immunology; D016027:Heart Transplantation / Q000276:immunology / Q000401:mortality; D006801:Humans; D015994:Incidence; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009894:Opportunistic Infections / Q000453:epidemiology / Q000401:mortality; D015995:Prevalence; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D012737:Sex Factors; D016019:Survival Analysis; D015996:Survival Rate
D001323:Autoantibodies; D006680:HLA Antigens